Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL

References

• Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782–7
   Google Scholar
• Beckman JA, Creager MA, Lbby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology and management. JAMA 2002;287:2570–81
   Google Scholar
• UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS38. BMJ 1998;351: 1755–62
   Google Scholar
• Keilers R. A primary care approach to comprehensive care of patients with type 1 and type 2 diabetes mellitus. J Am Osteopath Assoc 2003;103:53–7
   Google Scholar
• American Diabetes Association. Diabetic Nephropathy. Diabetes Care 2002;25:S85–9
   Web of Science ®Google Scholar
• American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003;26:917–32
   PubMed Web of Science ®Google Scholar
• Brenner B, Cooper M, de Zeeuw D, Keane W, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–9
   PubMed Web of Science ®Google Scholar
• Lindholm L, Ibsen H, Dahlof B, Devereux R, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:1004–10
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345: 870–8
   Google Scholar
• The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145–53
   Google Scholar
• Virberti G, Wheeldon NM. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106: 672–8
   Google Scholar
• American Heart Association. Heart disease and stroke statistics – 2003 Update. 2003:11–13,33–34
   Google Scholar
• Major cardiovascular disease (CVD) during 1997–1999 and major CVD hospital discharge rates in 1997 among women with diabetes – United States. MMWR Morb Mortal Wkly Rep 2001;50:948–54
   PubMedGoogle Scholar
• Kothari V, Stevens R, Adler A, Stratton I, et al. UKPDS 60 risk of stroke in type 2 diabetes estimated by the UK prospective diabetes study risk engine. Stroke 2002;33:1776–81
   PubMed Web of Science ®Google Scholar
• Brandle M, Zhou H, Smith B, Marriott D, et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26:2300–4
   PubMed Web of Science ®Google Scholar
• Elliott WJ. The economic impact of hypertension. J Clin Hypertens 2003;5:3–13
   PubMedGoogle Scholar
• Atlas of ESRD in the United States, One. Incidence and prevalence of ESRD. Am J Kidney Dis 2000;36:S37–54
   Google Scholar
• Atlas of ESRD in the United States, Eleven. Economic costs of ESRD. Am J Kidney Dis 2000;36:S163–76
   Google Scholar
• Arthur T, Zalemski S, Giermek D, Lamb C. Educating community providers changes beliefs towards caring for the ESRD patient. Adv Ren Replace Ther 2000;7:85–91
   PubMedGoogle Scholar
• The Heart Outcomes Prevention Evaluation (HOPE) Study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO–HOPE substudy. Lancet 2000;355:253–9
   Google Scholar
• Lewis E, Hunsicker L, Clarke W, Berl T, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–60
   PubMed Web of Science ®Google Scholar
• Brenner B, Cooper M, de Zeeuw D, Grunfeld JP, et al. The losartan renal protection study-rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 2000;1:328–35
   PubMedGoogle Scholar
• Dahlof B, Devereux RB, de Faire U, et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study: rationale, design, and methods. Am J Hypertens 1997;10:705–13
   PubMed Web of Science ®Google Scholar
• Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000;23:754–8
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206–52
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Lewis JB. ACE inhibitors versus angiotensin receptor blockers in diabetic nephropathy: is there a winner? J Am Soc Nephrol 2004;15:1358–60
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2003;26:S80–2
   PubMedGoogle Scholar
• Jafar TH, Starck PC, Schmid CH, Landa M, et al. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition. A patient-level meta-analysis. Ann Intern Med 2003;139:244–52
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, Julius S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002:359;995–1003
   PubMed Web of Science ®Google Scholar